SCHEMBL6349693

SCHEMBL6349693

CC(C)(C)CC(C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
CYP2C9 P11712 4/20 0.50
CYP2C19 P33261 4/20 0.50
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.46
CYP2D6 P10635 3/20 0.46
GRN P28799 1/20 0.42
SORT1 Q99523 1/20 0.42
BRD4 O60885 1/20 0.42
GABBR2 O75899 3/20 0.41
GABBR1 Q9UBS5 3/20 0.41
LMNA P02545 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 2/20 0.41
TSHR P16473 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
NFKB1 P19838 1/20 0.41
DRD3 P35462 1/20 0.41
BLM P54132 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27886529 0.84 ESR1 (0.47) POLBCYP2C9CYP2C19CYP2D6LMNA
SCHEMBL681512 0.83 CYP2C19 (0.52) POLBCYP2C19CYP2D6LMNAMAPK1
SCHEMBL681077 0.83 CYP2C19 (0.52) POLBCYP2C19CYP2D6LMNAMAPK1
SCHEMBL679845 0.83 CYP2C19 (0.52) POLBCYP2C19CYP2D6LMNAMAPK1
SCHEMBL20993330 0.81 FFAR2 (0.53) POLBKMT2AMEN1BRD4L3MBTL1
SCHEMBL2580056 0.80 POLB (0.46) POLBCYP2C9CYP2C19KMT2AMEN1
SCHEMBL7711076 0.79 POLB (0.58) POLBCYP2C9CYP2C19KMT2AMEN1
SCHEMBL16075922 0.79 POLB (0.58) POLBCYP2C9CYP2C19KMT2AMEN1
SCHEMBL1742115 0.79 POLB (0.58) POLBCYP2C9CYP2C19KMT2AMEN1
SCHEMBL12985331 0.77 POLB (0.56) POLBCYP2C9CYP2C19KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849649-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. (US) 2005-02-01 US disclosed
US-20040106611-A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC 2004-06-03 US disclosed
EP-1373192-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD Pfizer Limited (GB) 2004-01-02 EP disclosed
US-6660756-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-12-09 US disclosed
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-06-05 US disclosed
WO-2002079143-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD PFIZER LIMITED (GB) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP POLB 3308/4885CYP2C9 1050/4885CYP2C19 792/4885
US-20040106611-A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP POLB 3018/4885CYP2C9 1171/4885CYP2C19 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.